A seemingly most effective target for early detection and intervention of prostate tumor invasion

Journal of Cancer

Volumn 1, Issue 1, 2010, Pages 63-69

  Man, Yan Gao ^a,b  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b JILIN UNIVERSITY   (China)

Author keywords

Basal cells; Early detection; Invasion; Prostate cancer; Stem cells; Tumor cell budding

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; UVOMORULIN;

APOPTOSIS; ARTICLE; BASAL CELL; CANCER DIAGNOSIS; CANCER INVASION; CELL BUDDING; CELL DISRUPTION; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL EFFECTIVENESS; EARLY DIAGNOSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; NONHUMAN; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TUMOR CELL;

EID: 79952461537     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.1.63     Document Type: Article

References (42)

1. Carruba G, Stefano R, Cocciaeliferro L. Intercellular communication and human prostate carcinogenesis. Ann NY Acad Sci 2002; 963:156-168.
2. Goldstein NS, Underhiel J, Roszka N, Neill JS. Cytokeratin 34 beta E-12 immunoreactivity in benign prostate acini. Quantitation, pattern assessment, and electron microscopic study. Am J Clin Pathol 1999; 112:69-74.
3. Bonkhoff H, Wernert N, Dhom G, Remberger K. Basement membranes in fetal, adult normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 1991; 418:375-381.
4. Bonkhoff H, Remberger K. Morphogenesis of benign prostatic hyperplasia and prostatic carcinoma. Pathology 1998; 19: 12-20.
5. Bostwick DG. Prospective origins of prostate carcinoma. Prostate intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 1996; 78: 330-336.
6. Haggman MJ, Macoska JA, Wojno KJ, Oesterling JE. The relationship between prostate intraepithelial neoplasia and prostate cancer: critical issues. J Urol 1997; 58:12-22.
7. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996; 28: 98-106.
8. Barsky SH, Siegal GP, Jannotta F, Liotta LA. Loss of basement membrane components by invasive tumors but not by the benign counterparts. Lab Invest 1983; 49:140-147.
9. Kosir MA, Wang W, Zukowski KL, Tromp G. Degradation of basement membrane by prostate tumor heparanase. J Surg Res 1999; 81:42-47.
10. Goldfarb RH, Liotta LA. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost 1986; 12: 294-307.
11. Gardner WA, Culberson DE. Atrophy and proliferation in the young adult Prostate. J Urol 1987; 137 (1): 53-56.
12. Gardner WA. Hypothesis: Pediatric Origins of Prostate Cancer. Hum Path. 1995; 26:1291-1292.
13. Bennett BD, Gardner WA. Embryonal hyperplasia of the prostate. The Prostate 1985; 3 (7): 411-417.
14. Malins DC, Polissar NL, Su Y, Gardner HS, Gunselman SJ. A new structural analysis of DNA using statistical models of infrared sepctra. Nat Med 1997; 3: 927-930.
15. Malins DC, Johnson PM, Barker EA, Pollssar NL, Wheeler TM, Anderson KM. Cancer-related changes in prostate DNA as men age and early identification of metastasis in prostate tumors. Proc Natl Acad Sci USA 2003; 100: 5401-5406.
16. Malins DC, Anderson KM, Gilman NK, Green VM, Barker EA, Anderson KM. Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci Sci USA 2004; 101:10721-10725.
17. Malins DC, Gilman NK, Green VM, Wheeler TM, Barker EA, Anderson KM. A DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci USA 2005; 102: 19093-19096.
18. Harvei S, Skijorten FJ, Robsahm TE, Berner A, Tretli S. Is prostatic intraepithelial neoplasi in the transitio/central zone a true presursor of cancer? A long-term retrospective study in Norway. Br J Cancer 1998; 78:46-49.
19. Goeman L, Joniau S, Ponette D, Van der Aa F, Roskams T, Oyen R, Van Poppel H. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer. Prostate Cancer Prostatic Dis 2003; 6:305-310.
20. Mostofi FK, Sesterhenn IA, Davis CJ Jr. Prostatic intraepithelial neoplasia (PIN): morphological clinical significance. Prostate Suppl 1992; 4:71-77.
21. Kasahara Y, Tsukada Y. New insights and future advances in cancer diagnostics: Limitations of conventional tumor markers. In: Nakarnura RM, Grody WW, Wu JT, Nagle RB, editors. Cancer Diagnostics: Current and future trends. Totowa, NJ: Humanna Press. 2004: 15-26.
22. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trial and tribulations. Science 2002; 295 (5564): 2387-2392.
23. Matrisian LM, Sledge GW Jr, Mohla S. Exacellular proteolysis and cancer: meeting summary and future directions. Cancer Res 2003; 63: 6105-6109.
24. Ashida S, Nakagawa H, Katagiri T, Furihata M, Liizumi M, Anazawa Y, et al. Molecular features of the transition from prostate intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 2004; 64:5963-5872.
25. Dawkins HJ, Sellner LN, Turbett GR, Thompson CA, Redmond SL, MeNeal JE, Cohen RJ. Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adecarcinoma, using molecular markers of cancer progression. Prostate 2000; 44:265-270.
26. Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila Pa). 2008 1(3):167-73.
27. Cornud F, Bellin MF, Portalez D. MRI and staging evaluation of prostate cancer. J Radiol. 2006; 87(2 Pt 2):228-243.
28. Haggman MJ, Adolfsson J, Khoury S, Montie JE, Norlen J. Clinical managment of premalignant lesions of the prostate. WHO Collaborative Project and Consensus Conference on Public Health and Clinical Significance of Premalignant Alterations in the Genitourinary Tract. Scand J Urol Nephol Suppl 2000; 205:44-49.
29. Bostwick DG, Qian J, Frankel K. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol 1985; 154: 1791-1784.
30. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157:1769-1775.
31. Kurita T, Medina RT, Mills AA, Cunha GR. Role of p63 and basal cells in prostate. Development 2004; 131: 4955-4964.
32. Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell R, et al. Maspin expression profile in human prostate cancer (caP) and in vitro induction of maspin expression by androgen ablation. Clin Cancer Res 2002; 8(5):1172-1177.
33. Cher ML, Biliran HR jr, Bhangat S, Meng Y, Che M, Lockett J. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in animal model of prostate cancer bone metastasis. Proc Natl Acad Sci USA 2003; 100(13): 7847-7852.
34. Man YG, Shen T, Zhao YG, Sang QX. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion. Cancer Detect Prev 2005; 29: 161-169.
35. Man YG, Zhao CQ, Wang J, XL Chen. A subset of prostate basal cells lacks corresponding phenotypic markers. Pathol Res Pract 2006; 202 (9): 651-662.
36. Man YG and Gardner WA. Focal degeneration of basal cells and the resultant autoimmune- reactions: a novel mechanism for prostate tumor progression and invasion. Med Hypotheses 2008; (70):387-408.
37. Man YG, Gardner WA. Bad seeds produce bad crops: a single step-process of prostate carcinogenesis and Progression. Int J Biol Sci 2008; 4: 246-258.
38. Liu AJ, Wei LX, Gardner WA, Man YG. Correlated alterations in prostate basal cell layer and basement membrane. Int J Biol Sci 2009; 5: 276-285.
39. Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y, et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer 2009; 115(14): 3324-3334.
40. Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, O'Donoghue D, Sheahan K. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009; 33(1): 134-141.
41. Hart IR. New evidence for tumor embolism as a model of metastasis. J Pathol 2009; 219 (3): 275-276.
42. Zhu G, Reynolds L, Crnogorac-Jurceic T, Gillett CE, Dublin EA, Marshall JF, et al. Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells of breast cancer. Oncogene 2003; 22:3742-3748.